Related Experiment Video
Updated: Jun 7, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Enhanced tumor suppression in colorectal cancer via berberine-loaded PEG-PLGA nanoparticles
Fei Shen1,2, Yun-Sheng Zheng2, Lan Dong2
1Department of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Abstract:
Colorectal cancer (CRC) stands as the third most widespread cancer globally with poor prognosis. Berberine (Ber), as one herbal phytochemical, showed promise in CRC therapy, but its exact mechanism is unclear. Small molecule traditional drugs face challenges in quick metabolism and low bio-availability after systemic administration. Nanodrug deliver system, with their unique properties, has the advantages of protecting drugs, improving drug bio-availability, and reducing toxic and side effects, which exhibited huge drug delivery potential. Herein, the PEG-PLGA nanocarrier was used for encapsulated Ber according to nanoprecipitation and obtained nanomedicine, denoted as NPBer. In vitro, the flow cytometry test and CCK8 assays indicated that NPBer was more easily taken up by HCT116 CRC cells, and had stronger inhibition on cell proliferation with the increase of drug concentration. In addition, RNA-Seq was employed to explore the alterations in the transcriptomes of cancer cells subsequent to treatment with Free Ber or NPBer.The sequencing results indicate that Free Ber could activate cellular aging mechanisms, intensified the iron death pathway, optimized oxidative phosphorylation efficiency, exacerbated apoptosis, accelerated programmed cell death, and negatively modulated key signaling pathways in CRC cells including Wnt, TGF-beta, Hippo, and mTOR signaling pathways. Based on PEG-PLGA nanocarriers, NPBer can improve the in vivo delivery efficiency of Ber, thereby enhancing its antitumor efficacy in vivo, enhancing apoptosis by enhancing the mitochondrial autophagy and autophagy activities of CRC cells, negatively regulating the inflammatory mediator to regulate TRP channels, and inhibiting the activation of Notch signaling pathway. In vivo, NPBer can significantly improve its accumulation and durable drug targeting in tumor site, resulting in induce maximum cell apoptosis and effectively inhibit the proliferation of HCT116 tumor. This strategy provided a promising antitumor therapeutic strategy using Ber-based drugs.
Insights
Berberine (Ber) encapsulated in PEG-PLGA nanocarriers (NPBer) enhances colorectal cancer (CRC) cell apoptosis and inhibits tumor growth. This nanodrug delivery system improves Ber
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Colorectal cancer (CRC) is a leading global cancer with poor outcomes.
- Berberine (Ber), a natural compound, shows potential against CRC but suffers from poor bioavailability.
- Nanodrug delivery systems offer advantages in drug protection, bioavailability, and reduced toxicity.
Purpose of the Study:
- To develop and evaluate Berberine-loaded PEG-PLGA nanocarriers (NPBer) for enhanced colorectal cancer therapy.
- To investigate the in vitro and in vivo anti-cancer mechanisms of NPBer compared to free Berberine.
Main Methods:
- Nanoprecipitation was used to encapsulate Berberine into PEG-PLGA nanocarriers, forming NPBer.
- In vitro studies utilized flow cytometry and CCK8 assays to assess NPBer uptake and cytotoxicity in HCT116 CRC cells.
- RNA-sequencing (RNA-Seq) analyzed transcriptomic alterations induced by Free Ber and NPBer treatments.
- In vivo studies evaluated NPBer's tumor targeting, accumulation, and anti-proliferative effects.
Main Results:
- NPBer demonstrated enhanced cellular uptake and stronger inhibition of HCT116 CRC cell proliferation compared to Free Ber.
- RNA-Seq revealed that Free Ber induced cellular aging, ferroptosis, apoptosis, and modulated key CRC signaling pathways (Wnt, TGF-beta, Hippo, mTOR).
- NPBer significantly improved in vivo drug delivery, enhanced apoptosis via mitochondrial autophagy, and inhibited Notch signaling.
- In vivo, NPBer exhibited superior tumor accumulation, sustained drug targeting, induced maximal apoptosis, and effectively inhibited HCT116 tumor growth.
Conclusions:
- PEG-PLGA nanocarrier encapsulation enhances Berberine's anti-cancer efficacy against colorectal cancer.
- NPBer represents a promising therapeutic strategy for colorectal cancer by improving drug delivery and augmenting antitumor mechanisms.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules